Xpeedy^® mSPE – Magnetic Extraction, Reimagined

Magnetic Bead-based Solid Phase Extraction (mSPE) that enables scalable, high-throughput extraction where traditional workflows fail

Beyond SPE

Xpeedy^® mSPE uses functionalized magnetite (Fe₃O₄) micro-particles as a dispersed sorbent, enabling small-molecule extraction through a suspension-based adsorption and release mechanism. By eliminating flow-through constraints, the platform delivers consistent performance across complex matrices while supporting flexible, application-specific workflows.

Key Features

• Dispersed magnetic sorbent enables rapid interaction 

• Eliminates channeling and flow-dependent variability 

• No packed beds or pressure-driven processing 

• Tailorable surface chemistry for diverse analytes 

• Compatible with complex biological matrices 

• Enables automated and a common workflow across expanding matrix types
  

Proven Success

Xpeedy^® mSPE has demonstrated robust performance in challenging biological matrices including Quantisal™ fortified oral fluid and whole blood. In oral fluid alone, over 81 analytes have been successfully extracted in high-complexity clinical labs, with that list continuing to grow. 

In whole blood, through collaboration with a team at Children's Hospital of Los Angeles, the platform demonstrated high extraction recoveries, minimal matrix effects, and strong agreement with validated LC–MS/MS methods for a panel of immunosuppressants.

Conference Proceedings Conference Proceedings

• Xpeedy^® mSPE AutoPrep Platform for Multi-Matrix LC–MS/MS Toxicology

ADLM 2026 Disruptive Technology Award Submission

• A High-Throughput, Fully Automated Magnetic Bead-Based Extraction for Multi-Class Drug of Abuse Analysis in Oral Fluid

Accepted ADLM 2026 Poster Abstract

• Streamlining Immunosuppressant Quantification: Evaluation of Automated Magnetic Bead-Based Solid-Phase Extraction (mSPE) for Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Accepted ADLM 2026 Poster Abstraction (in collaboration with Dr. Yi Xiao and Dr. Edward Leung at Children’s Hospital of Los Angeles)

Pending Patents

• Fully Automated Sample Preparation System and Methods (U.S. Provisional Patent Application No. 63/690,072)

• Automated Sample Preparation System and Methods (International Patent Application No. PCT/US25/59559)

• Devices and Methods for Collecting and Retaining Fluid Samples (U.S. Provisional Patent Application No. 63/887,025)

Transversal Therapeutics – Quantitative Diagnostics at Point-of-Need

Transversal is a CURA subsidiary developing a next-generation electrochemical platform for rapid, high-sensitivity detection of small molecules from minimal sample volumes, enabling accurate, quantitative, diagnostics directly at point-of-care.

Electrochemical Detection for Rapid, Quantitative Diagnostics

Transversal's electrochemical sensing platform utilizes proprietary sensing technology to enable rapid, quantitative detection of small molecules from small volumes using a compact, cartridge-based system. Nanostructured electrodes and competitive immunoassay chemistry generate measurable electrical output, translating molecular interactions into precise results without complex instrumentation. In contrast to laboratory gold standards such as LC-MS/MS, which require centralized infrastructure and multi-step workflows, Transversal’s platform enables fast, on-demand measurement in near-patient settings while remaining compatible with decentralized laboratory environments.

Designed for Point-of-Care and Beyond

The platform is being developed as a cartridge-based system integrating sample handling, incubation, and electrochemical detection within a compact analyzer. This approach is intended to enable quantitative testing from small sample volumes obtained via minimally invasive sampling.

Target capabilities include:

• Rapid turnaround times (≤20 minutes)

• Quantitative results at clinically relevant concentrations

• Low sample volume requirements (finger-prick compatible)

• Automated, simplified workflows

The platform is analyte-agnostic, enabling new targets to be added through assay chemistry without redesigning the core system. This flexibility supports expansion across applications including therapeutic drug monitoring, clinical toxicology, chemical exposure diagnostics, and broader biomarker detection.

Peer-reviewed Publications

• A Rapid Label-Free Disposable Electrochemical Salivary Point-of-Care Sensor for SARS-CoV-2 Detection and Quantification, ACS Sensors, 2021

• State of the Art and New Perspectives for Non-Invasive Point-of-Care Testing, Biotechnology Advances, 2016

• Noninvasive Glucose Monitoring Using Saliva Nano-Biosensor, Sensing and Bio-Sensing Research, 2014

• DNA-Functionalized Single-Walled Carbon Nanotube-Based Sensor Array for Breath Analysis, Nano Letters, 2013

• An On-Chip Disposable Salivary Glucose Sensor for Diabetes Control, Journal of Diabetes Science and Technology, 2012

• Sensing of Salivary Glucose Using Nanostructured Biosensors, Sensors and Actuators B: Chemical, 2011

• On-Chip Ultra-Sensitive Glucose Sensing Using Multilayer Films Composed of Single-Walled Carbon Nanotubes, Gold Nanoparticles, and Glucose Oxidase, Analytical Chemistry, 2011

Granted Patents

• Durable Enzyme-Based Biosensors Platform Enabled by a Drop Deposition Immobilization Process (U.S. Patent No. 10,851,059 B2)

• Saliva Glucose Monitoring System (U.S. Patent No. 8,784,602 B2)

Learn more at Transversal's website at www.transversal-tx.com / or contact them at contact@transversal-tx.com